iRadimed (IRMD) Stock Price, News & Analysis

Company Overview

iRadimed Corporation is a medical device company specializing in the design, manufacture and distribution of infusion systems and accessories engineered specifically for use in magnetic resonance imaging (MRI) environments. The company’s products enable a wide range of MRI-guided diagnostic and therapeutic procedures by delivering precise, uninterrupted intravenous fluids, contrast agents and medications directly to patients during imaging studies. By addressing the unique safety and electromagnetic compatibility requirements of MRI suites, iRadimed’s offerings help hospitals and outpatient imaging centers optimize workflow and improve patient care.

The company’s flagship product line, known as TRIM, includes MRI-compatible infusion pumps that feature nonferromagnetic construction and low-interference electronics. These pumps are complemented by a suite of ancillary devices such as dual-syringe modules, MRI-safe infusion sets and monitoring accessories designed to integrate seamlessly with existing imaging equipment. iRadimed also provides comprehensive technical support, training and maintenance services to ensure that clinical teams can operate its systems effectively and in compliance with regulatory standards.

Founded in the late 1990s, iRadimed has grown from a niche supplier of specialized pumps into a recognized leader in MRI infusion technology. The company holds multiple patents covering its core pump mechanisms and control systems, and it maintains quality management certification under international medical device regulations. With manufacturing facilities located in central Florida, iRadimed oversees all stages of product development in-house, from research and prototyping to final assembly and distribution.

iRadimed serves customers across North America, Europe, Asia-Pacific and select emerging markets through a combination of direct sales and a global network of distribution partners. The company is led by President and Chief Executive Officer Euan S. Thomson, who brings extensive experience in medical device innovation and business development. Under Thomson’s leadership, iRadimed continues to invest in new product enhancements and strategic collaborations to expand its footprint in the diagnostic imaging sector.

Key Stats

• Today's Range: $61.20 to $62.25
• 50-Day Range: $51.01 to $61.83
• 52-Week Range: $42.34 to $63.29
• Volume: 69,139 shs
• Average Volume: 43,992 shs
• Market Capitalization: $786.48 million
• P/E Ratio: 39.89
• Dividend Yield: 1.10%
• Price Target: $72.00
• Consensus Rating: Buy

iRadimed Stock Analysis - MarketRank™

iRadimed scored higher than 94% of companies evaluated by MarketBeat, and ranked 72nd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

iRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

iRadimed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 20.48%

Earnings Growth

Earnings for iRadimed are expected to grow by 20.48% in the coming year, from $1.66 to $2.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iRadimed is 39.89, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.61.

Price to Earnings Ratio vs. Sector

The P/E ratio of iRadimed is 39.89, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.43.

Price to Book Value per Share Ratio

iRadimed has a P/B Ratio of 9.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.97% of the float of iRadimed has been sold short.

Short Interest Ratio / Days to Cover

iRadimed has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in iRadimed has recently increased by 3.75%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

iRadimed pays a meaningful dividend of 1.10%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

iRadimed has only been increasing its dividend for 1 years.

Dividend Coverage

The dividend payout ratio of iRadimed is 43.87%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, iRadimed will have a dividend payout ratio of 34.00% next year. This indicates that iRadimed will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

2.97% of the float of iRadimed has been sold short.

Short Interest Ratio / Days to Cover

iRadimed has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in iRadimed has recently increased by 3.75%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

iRadimed has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iRadimed insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.80% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IRMD Stock Analysis - Frequently Asked Questions

How have IRMD shares performed this year?

iRadimed's stock was trading at $55.00 at the start of the year. Since then, IRMD shares have increased by 12.4% and is now trading at $61.83.

How were iRadimed's earnings last quarter?

iRadimed Corporation (NASDAQ:IRMD) announced its earnings results on Thursday, February, 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by $0.05. The medical equipment provider earned $19.39 million during the quarter, compared to analyst estimates of $19.09 million. iRadimed had a trailing twelve-month return on equity of 23.28% and a net margin of 26.33%.
Read the conference call transcript.

How do I buy shares of iRadimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iRadimed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 2/13/2025
• Record date for 5/30 Dividend: 5/20/2025
• Ex-Dividend for 5/30 Dividend: 5/20/2025
• Dividend Payable: 5/30/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRMD
• CIK: 1325618
• Web: www.iradimed.com
• Phone: (407) 677-8022
• Fax: 407-677-5037
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $72.00
• High Stock Price Target: $72.00
• Low Stock Price Target: $72.00
• Potential Upside/Downside: +16.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.55
• Trailing P/E Ratio: 39.89
• Forward P/E Ratio: 37.25
• P/E Growth: N/A
• Net Income: $19.23 million
• Net Margins: 26.33%
• Pretax Margin: 33.23%
• Return on Equity: 23.28%
• Return on Assets: 20.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.87
• Quick Ratio: 7.62

Sales & Book Value

• Annual Sales: $73.24 million
• Price / Sales: 10.74
• Cash Flow: $1.58 per share
• Price / Cash Flow: 39.06
• Book Value: $6.85 per share
• Price / Book: 9.03

Miscellaneous

• Outstanding Shares: 12,720,000
• Free Float: 8,036,000
• Market Cap: $786.48 million
• Optionable: Optionable
• Beta: 0.91